Oculoplastics

Mycophenolate mofetil appears to be effective second-line treatment for TED

Mycophenolate mofetil (MMF) appears safe and effective as a second-line immunosuppressive agent in patients with thyroid eye disease (TED), according to a study.

In this retrospective cohort study, 20 patients with active moderate-severe to sight-threatening TED were followed over 4 years (Weeks 24, 52 and 78) to evaluate the clinical efficacy of MMF dosing and side effects.

The median…

Read More


featured stories

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Conference Roundup

  1. May 04, 2021

What is a Rainbow Brow?

In a presentation at ARVO 2021, Emery Jamerson, MD, described “Rainbow Brow”- a novel physical exam finding in patients with thyroid eye disease (TED). Eyes with Rainbow Brow have a statistically significant difference in eyebrow curvature than eyes with TED without it.

Researchers…

View All

Journal Scan

  1. Jun 02, 2021

Mycophenolate mofetil appears to be effective second-line treatment for TED

Mycophenolate mofetil (MMF) appears safe and effective as a second-line immunosuppressive agent in patients with thyroid eye disease (TED), according to a study.

In this…

View All

Trending Topics

  1. Apr 01, 2021

Oxymetazoline hydrochloride 0.1% helps fill unmet need for patients with ptosis

By Derek N. Cunningham, OD

Although mild to moderate ptosis is common, affecting about 12% of the population older than 50,1,2 many eye care specialists are hesitant to engage these patients. Until now, surgery—which is not…

View All

Resources